Moxifloxacin Hcl



Indications and Reactions:

Role Indications Reactions
Primary
Drug Use For Unknown Indication 23.7%
Pneumonia 10.1%
Pulmonary Tuberculosis 7.8%
Prophylaxis 7.4%
Sepsis 7.1%
Anaesthesia 6.8%
Bronchitis 4.7%
Tuberculosis 3.7%
Chronic Obstructive Pulmonary Disease 3.5%
Hypertension 3.4%
Upper Respiratory Tract Infection 3.4%
Sinusitis 2.8%
Pain 2.7%
Septic Shock 2.6%
Infection 2.1%
Bradycardia 1.7%
Infection Prophylaxis 1.7%
Product Used For Unknown Indication 1.7%
Respiratory Tract Infection 1.7%
Atypical Mycobacterial Infection 1.4%
Vomiting 11.0%
Rash 8.4%
Bradycardia 7.1%
Pyrexia 7.1%
Clostridium Difficile Colitis 6.5%
Thrombocytopenia 6.5%
Urticaria 6.5%
Torsade De Pointes 5.2%
International Normalised Ratio Increased 4.5%
Renal Failure Acute 4.5%
Ventricular Tachycardia 4.5%
Pneumonia Aspiration 3.9%
Tendonitis 3.9%
Diarrhoea 3.2%
Rhabdomyolysis 3.2%
Wheezing 3.2%
Clostridial Infection 2.6%
Hypotension 2.6%
Tachycardia 2.6%
Uveitis 2.6%
Secondary
Product Used For Unknown Indication 21.7%
Drug Use For Unknown Indication 19.8%
Pneumonia 7.9%
Sepsis 5.6%
Rheumatoid Arthritis 4.9%
Septic Shock 4.1%
Respiratory Tract Infection 3.8%
Bronchitis 3.6%
Mycobacterial Infection 3.6%
Pulmonary Tuberculosis 3.4%
Hiv Infection 3.0%
Pneumonia Legionella 2.6%
Hypertension 2.4%
Anaesthesia 2.3%
Pain 2.1%
Prophylaxis 2.1%
Atrial Fibrillation 1.9%
Chronic Obstructive Pulmonary Disease 1.9%
Disseminated Tuberculosis 1.7%
Ill-defined Disorder 1.7%
International Normalised Ratio Increased 9.6%
Bradycardia 8.5%
Thrombocytopenia 8.5%
Pneumonia 7.4%
Renal Failure 7.4%
Clostridium Difficile Colitis 6.4%
Urticaria 6.4%
Vomiting 6.4%
Rhabdomyolysis 5.3%
Cytolytic Hepatitis 4.3%
Electrocardiogram Qt Prolonged 4.3%
Drug Exposure During Pregnancy 3.2%
Drug Rash With Eosinophilia And Systemic Symptoms 3.2%
Sudden Death 3.2%
Tendon Rupture 3.2%
Vertigo 3.2%
Xerophthalmia 3.2%
Corneal Deposits 2.1%
Diarrhoea 2.1%
Hypersensitivity 2.1%
Concomitant
Drug Use For Unknown Indication 53.5%
Prophylaxis 4.1%
Multiple Myeloma 3.9%
Pain 3.9%
Pneumonia 3.5%
Hiv Infection 3.3%
Non-small Cell Lung Cancer 3.0%
Tuberculosis 2.7%
Product Used For Unknown Indication 2.7%
Hypertension 2.6%
Constipation 2.3%
Acute Lymphocytic Leukaemia 1.9%
Acute Myeloid Leukaemia 1.9%
Nausea 1.8%
Asthma 1.5%
Pulmonary Tuberculosis 1.5%
Breast Cancer 1.4%
Infection 1.4%
Thrombosis Prophylaxis 1.4%
Renal Transplant 1.4%
Vomiting 12.7%
Pyrexia 8.5%
Weight Decreased 7.7%
White Blood Cell Count Decreased 7.0%
Renal Failure Acute 5.6%
Sepsis 5.6%
Toxic Epidermal Necrolysis 5.6%
White Blood Cell Count Increased 5.6%
Respiratory Failure 4.9%
Somnolence 4.9%
Urticaria 4.2%
Viral Haemorrhagic Cystitis 4.2%
Thrombocytopenia 3.5%
Hypoxia 2.8%
International Normalised Ratio Increased 2.8%
Prostate Cancer 2.8%
Pulmonary Embolism 2.8%
Rash Vesicular 2.8%
Renal Failure 2.8%
Serotonin Syndrome 2.8%
Interacting
Pneumonia 31.1%
Breast Cancer Metastatic 16.4%
Pain 9.8%
Prophylaxis Against Gastrointestinal Ulcer 8.2%
Renal Failure Chronic 8.2%
Mitral Valve Replacement 6.6%
Drug Use For Unknown Indication 4.9%
Lung Infection 4.9%
Pyrexia 3.3%
Anticoagulant Therapy 1.6%
Depression 1.6%
Respiratory Tract Infection 1.6%
Thrombosis Prophylaxis 1.6%
International Normalised Ratio Increased 33.3%
Pseudomembranous Colitis 33.3%
Drug Interaction 8.3%
Electrocardiogram Qt Prolonged 8.3%
Peritoneal Haemorrhage 8.3%
Urinary Tract Infection 8.3%